
- /
- Supported exchanges
- / US
- / SILO.OTCQB
Silo Pharma Inc (SILO OTCQB) stock market data APIs
Silo Pharma Inc Financial Data Overview
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Silo Pharma Inc data using free add-ons & libraries
Get Silo Pharma Inc Fundamental Data
Silo Pharma Inc Fundamental data includes:
- Net Revenue: 72 102
- EBITDA: -4 699 509
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-03-25
- EPS/Forecast: -0.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Silo Pharma Inc News

Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Weedmaps co-founders withdrew buyout offer, but left door open for future deal High Tide launched “Buy Local” cannabis campaign across Canada to celebrate Canada Da...


Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
NEW YORK, Jun 25, 2025 - (JCN Newswire) - - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...

Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment
NEW YORK - Silo Pharma, Inc. (NASDAQ:SILO) announced Wednesday it has entered into a non-binding letter of intent with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to form a 50:50 joint venture focused on de...

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.